Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351668 | 1.00 | NR1H2 (0.45) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL2354787 | 1.00 | NR1H2 (0.45) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL18314503 | 0.91 | HPGD (0.43) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL2349492 | 0.91 | NR1H2 (0.44) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL2349491 | 0.91 | NR1H2 (0.44) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL17032300 | 0.91 | HPGD (0.43) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL13478901 | 0.89 | NR1H2 (0.50) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL13393217 | 0.89 | NR1H2 (0.50) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL10305452 | 0.89 | NR1H2 (0.50) | NR1H2HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL2382722 | 0.87 | HPGD (0.40) | HPGDRECQLEPHX1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566029-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IP2IPO INNOVATIONS LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| US-20210253583-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| US-10927119-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IP2IPO INNOVATIONS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200055862-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-10414772-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-3107914-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECH LTD (GB) | 2019-01-30 | — | — | EP | disclosed |
| US-20180273540-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| US-9932344-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| EP-2536283-B1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536283-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011103091-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-6509003-B2 | N-alkylpiperidine derivatives labeled with radioactive iodine; use in single photon emission computed tomography (SPECT) | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-0989120-B1 | REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY | DAIICHI PURE CHEMICALS CO LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-20020127180-A1 | Reagents for the determination of cerebral regional acetylcholinesterase activity | DAIICHI PURE CHEMICALS CO., LTD (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6306882-B1 | FLUOROALKYLPIPERIDINE ESTERS COGNITION ACTIVATORS AND ALZHEIMER'S | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0989120-A1 | REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253583-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | NR1H2 2619/4885HPGD 2147/4885RECQL 1816/4885 |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | AGER, PSEN2, PSEN1 | NR1H2 249/4885HPGD 218/4885RECQL 1279/4885 |
| US-10927119-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | NR1H2 2619/4885HPGD 2147/4885RECQL 1816/4885 |
| US-20200055862-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | NR1H2 2619/4885HPGD 2147/4885RECQL 1816/4885 |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | NR1H2 2257/4885HPGD 2092/4885RECQL 2442/4885 |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, PSEN2, PSEN1 | NR1H2 249/4885HPGD 218/4885RECQL 1279/4885 |
| US-20180273540-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | NR1H2 2619/4885HPGD 2147/4885RECQL 1816/4885 |
| US-20020127180-A1 | Reagents for the determination of cerebral regional acetylcholinesterase activity | ACHE, BCHE, CHAT | NR1H2 828/4885HPGD 1349/4885RECQL 1657/4885 |
| US-11566029-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | NR1H2 2619/4885HPGD 2147/4885RECQL 1816/4885 |
| US-10414772-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | NR1H2 2619/4885HPGD 2147/4885RECQL 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.